Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.47 |
---|---|
High | 0.4789 |
Low | 0.46 |
Bid | 0.461 |
Offer | 0.47 |
Previous close | 0.463 |
Average volume | 1.17m |
---|---|
Shares outstanding | 38.44m |
Free float | 32.06m |
P/E (TTM) | -- |
Market cap | 17.80m USD |
EPS (TTM) | -2.97 USD |
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
- Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
- Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease
- Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates
- Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024
- Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
- Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients
- Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
- Athira Pharma to Participate in Upcoming June Conferences
- Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
- Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
More ▼